Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
≥97% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C,Desiccated Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 1 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Biochem/physiol Actions
Gardiquimod is a potent and specific agonist for human or mouse Toll-like receptor 7 (TLR7). Also, at high concentration gardiquimod activates TLR8. Similarly to imiquimod, gardiquimod could mimic the effects of viral nucleic acids on the immune system.
Gardiquimod is developed as a new imidazoquinoline compound. It stimulates NF-κB (nuclear factor-κB) activation in cells expressing human or murine toll like receptor 7 (TLR7). Gardiquimod is found to be ten times more efficient than imiquimod. It induces splenocyte activation and prevents murine B16 melanoma growth and metastasis. Gardiquimod might serve as a therapeutic agent to prevent HIV-1 (human immunodeficiency virus - 1) transmission. It hinders the life cycle of HIV-1, by blocking the action of HIV-1 reverse transcriptase.
| Sonrisas canónicas | CCNCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N |
|---|---|
| IUPAC Name | 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol |
| InChIKey | FHJATBIERQTCTN-UHFFFAOYSA-N |
| INCHI | 1S/C17H23N5O/c1-4-19-9-13-21-14-15(22(13)10-17(2,3)23)11-7-5-6-8-12(11)20-16(14)18/h5-8,19,23H,4,9-10H2,1-3H3,(H2,18,20) |
| Isómeros SMILES | CCNCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N |
| Peso molecular | 313.4 |
| Reaxy-Rn | 19659786 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=19659786&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organoheterocyclic compounds |
| Clase | Quinolines and derivatives |
| Subclass | Imidazoquinolines |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Imidazoquinolines |
| Alternative Parents | Aminoquinolines and derivatives Imidazo-[4,5-c]pyridines Aralkylamines Aminopyridines and derivatives N-substituted imidazoles Imidolactams Benzenoids Tertiary alcohols Heteroaromatic compounds Dialkylamines Azacyclic compounds Primary amines Hydrocarbon derivatives |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Imidazoquinoline - Aminoquinoline - Imidazopyridine - Imidazo-[4,5-c]pyridine - Aminopyridine - Aralkylamine - N-substituted imidazole - Pyridine - Benzenoid - Imidolactam - Tertiary alcohol - Imidazole - Azole - Heteroaromatic compound - Secondary amine - Secondary aliphatic amine - Azacycle - Amine - Primary amine - Organooxygen compound - Organonitrogen compound - Alcohol - Hydrocarbon derivative - Organic nitrogen compound - Organic oxygen compound - Aromatic heteropolycyclic compound |
| Descripción | This compound belongs to the class of organic compounds known as imidazoquinolines. These are aromatic heterocyclic compounds containing an imidazole ring fused to a quinoline ring system. In some configurations, the imidazole ring shares a nitrogen atom with the quinoline moiety. |
| External Descriptors | Not available |
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Fecha | Articulo |
|---|---|---|---|
| Certificate of Analysis | Apr 03, 2026 | G274801 | |
| Certificate of Analysis | Apr 02, 2026 | G274801 | |
| Certificate of Analysis | Apr 02, 2026 | G274801 | |
| Certificate of Analysis | Apr 02, 2026 | G274801 | |
| Certificate of Analysis | Feb 05, 2026 | G274801 | |
| Certificate of Analysis | Nov 20, 2025 | G274801 | |
| Certificate of Analysis | Nov 20, 2025 | G274801 | |
| Certificate of Analysis | Nov 20, 2025 | G274801 | |
| Certificate of Analysis | Oct 13, 2025 | G274801 | |
| Certificate of Analysis | Oct 13, 2025 | G274801 | |
| Certificate of Analysis | May 12, 2025 | G274801 | |
| Certificate of Analysis | Mar 19, 2024 | G274801 | |
| Certificate of Analysis | Apr 17, 2023 | G274801 | |
| Certificate of Analysis | Apr 17, 2023 | G274801 |
| Solubilidad | Soluble in DMSO to 100 mM |
|---|---|
| Peso molecular | 313.400 g/mol |
| XLogP3 | 1.000 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 5 |
| Exact Mass | 313.19 Da |
| Monoisotopic Mass | 313.19 Da |
| Topological Polar Surface Area | 89.000 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 404.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |
| 1. Xiaolong Li, Lanlan Ma, Jueshuo Guo, Yaya Wei, Shijie Ma, Yaping Mai, Guojing Gou, Wenbao Zuo, Jianhong Yang. (2025) Synergistic anti-tumor effects of mRNA vaccine and PERK inhibitor combination in melanoma treatment. COLLOIDS AND SURFACES B-BIOINTERFACES, [PMID:40383023] [10.1016/j.colsurfb.2025.114808] |